Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

MilliporeSigma™ anti-MDM2 Clone: IF2,

Mouse Monoclonal Antibody

Supplier:  MilliporeSigma™ OP46100UG

Catalog No. OP46100UG


Only null left
Add to Cart

Description

Description

Specifically detects MDM2 Clone: IF2 in Human samples, and it is validated for Immunofluorescence, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation, Immuno Blotting

Increased expression of proto-oncogenes due to gene amplification can lead to cellular transformation in the absence of other mutagenic events. Recently, a novel gene termed MDM2, first identified in mouse as a small acentromeric extrachromosomal element, was shown to become oncogenic upon amplification and tumorigenic when overexpressed in NIH3T3 and Rat2 cells. The human homolog of MDM2 gene has been isolated and mapped to chromosome 12q13-q14, a region that is found to be amplified in human sarcomas. Sequence analysis of the murine, rat, and human MDM2 genes suggests that MDM2 may be involved in transcriptional regulation. MDM2 contains two putative metal-binding motifs, one of which shares similarity to known zinc finger transcriptional activators. MDM2 also contains a putative nuclear localization signal and an acidic domain of the type found in transcriptional activators. A functional role for MDM2 has recently been identified on the basis of experiments which demonstrate that MDM2 forms a stable complex with p53 in vivo. Furthermore, over-expression of MDM2 inhibits the ability of wild type p53 to stimulate expression of target genes, and this inhibition appears to result from MDM2 binding to the acidic activation domain of p53, thereby preventing p53 from directly contacting the transcriptional machinery. Interestingly, wild type p53 appears to positively regulate expression of the MDM2 gene. MDM2 amplification has been observed in sarcomas, and direct analysis of the MDM2 and p53 genes in sarcomas indicates that one or the other but not both of these genes is mutated in 70% of the tumors. Thus, it appears that genetic alterations in either p53 or MDM2 represent alternative mechanisms for inactivating the same growth suppressive pathway. Regulation of MDM2 expression by p53 also represents a potential feed back control of p53 function.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

MDM2
Monoclonal
Unconjugated
Mouse
100 μg
Primary
Human
Purified
Immunoblot, Immunofluorescence, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation
IF2
In 50mM sodium phosphate buffer, 0.2% gelatin.
human MDM2
RUO
Recognizes the ∽90kDa (apparent MW) MDM2 protein. Also recognizes isoforms of ∽57kDa and ∽74/76kDa by immunoblotting.
2°C to 8°C
IgG2b
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.

For Research Use Only